PPACA promises to eventually close the coverage gap for seniors.
ONE OF THE MAIN attractions of the reform legislation is its scheme to eliminate the contentious coverage gap in Medicare Part D, which imposes out-of-pocket costs on seniors with high drug bills.
Currently, Medicare beneficiaries who spend more than $2,830 on medicines hit the donut hole in which they pay the full cost of prescriptions. After drug outlays exceed $6,440, the government covers 95% of additional catastrophic costs. The reform law lays out a plan to close the gap over 10 years with much of the cost shouldered by pharmaceutical companies.
To provide some immediate relief, the government is giving a $250 rebate to beneficiaries who fall into the donut hole this year. Beginning next January, manufacturers will cover 50% of the cost of brand medicines filled by seniors in the gap.
At that point, policy makers consider the donut hole essentially closed because the remaining of 25% copays will be in line with beneficiary fees on drugs prior to hitting the coverage gap.
Closing the hole will cost more than $60 billion over 10 years, but it eliminates a major source of confusion and hardship for elderly patients and is expected to boost compliance with prescribed therapy. The lower cost to beneficiaries, moreover, will move seniors through the donut hole more quickly to catastrophic coverage.
-Jill Wechsler
Upended: Can PBM Transparency Succeed?
March 6th 2024Simmering tensions in the pharmacy benefit management (PBM) industry have turned into fault lines. The PBMs challenging the "big three" have formed a trade association. Purchaser coalitions want change. The head of the industry's trade group says inherent marketplace friction has spilled over into political friction.
Read More
In this episode of the "Meet the Board" podcast series, Briana Contreras, Managed Healthcare Executive editor, speaks with Ateev Mehrotra, a member of the MHE editorial advisory board and a professor of healthcare policy and medicine at Harvard Medical School. Mehtrotra is also a hospitalist at the Beth Israel Deaconess Medical Center in Boston. In the discussion, Contreras gets to know Mehrotra more on a personal level and picks his brain on some of his research interests including telehealth, alternative payment models and price transparency.
Listen
Inflation Reduction Act: Reforms to Patient Cost-Sharing
September 18th 2023Lower out-of-pocket costs for patients might put upward pressure on drug prices, as manufacturers face less price sensitivity, note Matthew Majewski and Rhett Johnson of Charles River Associates. But they also note that upward pressure on price is likely to be limited to the inflation rate as any additional price increase would need to be paid back to CMS in the form of inflation rebates.
Read More
Spending climbed by 2.7% in 2021. In 2020, it soared by 10.3%, fueled by federal government spending in response to the pandemic. The blizzard of calculations of 2021 healthcare spending by CMS’ actuaries also provides further evidence that utilization of healthcare services bounced back in 2021.
Read More